Physician profile
Daniel J Prohaska
NPI 1356318570
$4,664.43
in general payments reported to CMS, 2019-2025
20 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $2,576 · 2021: $302 · 2022: $398 · 2023: $94.60 · 2024: $750 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lima USA, INC. | $2,482.20 | 2019-2020 | |
| Stryker Corporation | $1,132.45 | 2019-2025 | Aequalis Ascend Flex, Aequalis Flex Revive, Tornier Perform Reversed Augmented Glenoid |
| Medacta USA, INC. | $253.83 | 2022-2025 | Reverse Shoulder |
| Zimmer Biomet Holdings, INC. | $179.31 | 2021-2022 | |
| Anika Therapeutics, INC. | $138.53 | 2022 | |
| Linvatec Corporation | $129.29 | 2021-2025 | Biobrace 23mm |
| Ferring Pharmaceuticals INC. | $77.08 | 2024-2025 | Euflexxa |
| Titan Surgical Group, LLC | $38.46 | 2023 | |
| Siemens Medical Solutions USA, INC. | $32.51 | 2021 | |
| Depuy Synthes Sales INC. | $30.26 | 2019-2023 | |
| Pfizer INC. | $29.09 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $23.72 | 2019 | |
| Heron Therapeutics, INC. | $22.91 | 2024 | Zynrelef |
| Pacira Therapeutics, INC. | $20.92 | 2020 | |
| Convatec INC. | $15.80 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrosurface Incorporated | $15.55 | 2019 | |
| Bioventus LLC | $14.66 | 2019 | |
| Fidia Pharma USA INC. | $14.52 | 2025 | Hymovis, Triluron |
| Encore Medical, LP | $13.34 | 2023 | Djo Surgical |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,183,025.83 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Prohaska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.